Oliver Bandmann

9.5k total citations · 2 hit papers
123 papers, 6.0k citations indexed

About

Oliver Bandmann is a scholar working on Neurology, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Oliver Bandmann has authored 123 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Neurology, 36 papers in Molecular Biology and 34 papers in Cellular and Molecular Neuroscience. Recurrent topics in Oliver Bandmann's work include Parkinson's Disease Mechanisms and Treatments (52 papers), Neurological disorders and treatments (24 papers) and Genetic Neurodegenerative Diseases (20 papers). Oliver Bandmann is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (52 papers), Neurological disorders and treatments (24 papers) and Genetic Neurodegenerative Diseases (20 papers). Oliver Bandmann collaborates with scholars based in United Kingdom, Germany and United States. Oliver Bandmann's co-authors include Stephen G. Kaler, Karl Heinz Weiss, Heather Mortiboys, Nicholas Wood, Jan Aasly, Philip W. Ingham, Mark Cookson, Sandrine Bretaud, Huw R. Morris and Krisztina K. Johansen and has published in prestigious journals such as The Lancet, Nature Communications and ACS Nano.

In The Last Decade

Oliver Bandmann

119 papers receiving 5.9k citations

Hit Papers

Wilson's disease and other neurological copper disorders 2014 2026 2018 2022 2014 2021 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Wilson's disease and other neurological copper disorders
    2014 707 citations Oliver Bandmann et al. profile →
  2. Progress towards therapies for disease modification in Parkinson's disease
    2021 252 citations Oliver Bandmann, Huw R. Morris et al. profile →

Peers

Oliver Bandmann
Kay L. Double Australia
Teresa G. Hastings United States
John K. Fink United States
Fabio A. Zucca Italy
Huajun Jin United States
Susanne A. Schneider Germany
Ikuko Miyazaki Japan
Isao Hozumi Japan
Junxia Xie China
Kay L. Double Australia
Oliver Bandmann
Citations per year, relative to Oliver Bandmann Oliver Bandmann (= 1×) peers Kay L. Double

Countries citing papers authored by Oliver Bandmann

Since Specialization
Citations

This map shows the geographic impact of Oliver Bandmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Bandmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Bandmann more than expected).

Fields of papers citing papers by Oliver Bandmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Bandmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Bandmann. The network helps show where Oliver Bandmann may publish in the future.

Co-authorship network of co-authors of Oliver Bandmann

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Bandmann. A scholar is included among the top collaborators of Oliver Bandmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Bandmann. Oliver Bandmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Keatinge, Marcus, Oliver Pearce, Petteri Piepponen, et al.. (2025). A zebrafish model of acmsd deficiency does not support a prominent role for ACMSD in Parkinson’s disease. npj Parkinson s Disease. 11(1). 118–118. 2 indexed citations
2.
Castelli, Lydia M., Ya-Hui Lin, Helen R. Flynn, et al.. (2023). The master energy homeostasis regulator PGC-1α exhibits an mRNA nuclear export function. Nature Communications. 14(1). 5496–5496. 29 indexed citations
3.
Payne, Thomas, Matthew Appleby, Ellen Buckley, et al.. (2023). A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease. Movement Disorders. 38(8). 1493–1502. 29 indexed citations
4.
Payne, Thomas, Matilde Sassani, Mark Dunning, et al.. (2023). Multimodal assessment of mitochondrial function in Parkinson's disease. Brain. 147(1). 267–280. 10 indexed citations
5.
6.
Shribman, Samuel, Aurélia Poujois, Oliver Bandmann, Anna Członkowska, & Thomas T. Warner. (2021). Wilson’s disease: update on pathogenesis, biomarkers and treatments. Journal of Neurology Neurosurgery & Psychiatry. 92(10). 1053–1061. 78 indexed citations
7.
Payne, Thomas, Matthew Appleby, Ellen Buckley, et al.. (2020). Abstracts. Movement Disorders Clinical Practice. 7(S2). 1 indexed citations
8.
Payne, Thomas, Matilde Sassani, Ellen Buckley, et al.. (2020). Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson’s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study. BMJ Open. 10(8). e038911–e038911. 21 indexed citations
9.
Jabbari, Edwin, John Woodside, Manuela Tan, et al.. (2019). The genetic and clinico‐pathological profile of early‐onset progressive supranuclear palsy. Movement Disorders. 34(9). 1307–1314. 16 indexed citations
10.
11.
Davis, Ryan L., et al.. (2019). 136 Mitochondrial biomarkers in parkinson’s disease. Journal of Neurology Neurosurgery & Psychiatry. 90(12). e38.2–e38. 1 indexed citations
12.
Simpson, Julie E., Lisa Watson, Heather Mortiboys, et al.. (2018). TIGAR inclusion pathology is specific for Lewy body diseases. Brain Research. 1706. 218–223. 10 indexed citations
13.
Barber, Thomas R., Michael Lawton, Michal Rolinski, et al.. (2017). Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder. SLEEP. 40(8). 114 indexed citations
14.
Hadjivassiliou, Marios, Pascale Aeschlimann, David S. Sanders, et al.. (2013). Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. Neurology. 80(19). 1740–1745. 107 indexed citations
15.
Cooper‐Knock, Johnathan, J. Robin Highley, Judith Hartley, et al.. (2013). Neurodegeneration caused by intronic expansions of C9ORF72 is a clinically heterogeneous but pathologically distinct disease. The Lancet. 381. S32–S32. 1 indexed citations
16.
Lo, Christine, Laura Flinn, & Oliver Bandmann. (2012). Heterozygous mutations in the FGF8, SHH and nodal/transforming growth factor beta pathways do not confer increased dopaminergic neuron vulnerability—A zebrafish study. Neuroscience Letters. 532. 55–58. 1 indexed citations
17.
Bretaud, Sandrine, Sarah MacRaild, Philip W. Ingham, & Oliver Bandmann. (2011). The Influence of the Zebrafish Genetic Background on Parkinson's Disease–Related Aspects. Zebrafish. 8(3). 103–108. 10 indexed citations
18.
Möller, J. Carsten, Björn Tackenberg, Monika Heinzel‐Gutenbrunner, et al.. (2008). Immunophenotyping in Tourette syndrome – a pilot study. European Journal of Neurology. 15(7). 749–753. 22 indexed citations
19.
Oertel, Wolfgang H. & Oliver Bandmann. (1999). Multiple system atrophy. Journal of neural transmission. Supplementum. 56. 155–164. 6 indexed citations
20.
Bandmann, Oliver, C. D. Marsden, & Nicholas Wood. (1998). Genetic aspects of Parkinson's disease. Movement Disorders. 13(2). 203–211. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kay L. Double Breakdown of academic impact, for papers by Teresa G. Hastings Breakdown of academic impact, for papers by John K. Fink Breakdown of academic impact, for papers by Fabio A. Zucca Breakdown of academic impact, for papers by Huajun Jin Breakdown of academic impact, for papers by Susanne A. Schneider Breakdown of academic impact, for papers by Ikuko Miyazaki Breakdown of academic impact, for papers by Isao Hozumi Breakdown of academic impact, for papers by Junxia Xie
Rankless by CCL
2026